Shares of Sophiris Bio Inc. (NASDAQ:SPHS) rose 11.2% on Thursday . The stock traded as high as $2.40 and last traded at $2.38, with a volume of 1,347,869 shares changing hands. The stock had previously closed at $2.14.

SPHS has been the topic of several recent research reports. Maxim Group reiterated a “buy” rating and issued a $4.00 price objective on shares of Sophiris Bio in a research report on Thursday, March 24th. Echelon Wealth Partners restated a “buy” rating and set a $5.00 price target on shares of Sophiris Bio in a research report on Friday, June 10th.

The company has a 50 day moving average price of $1.62 and a 200-day moving average price of $1.60. The company’s market cap is $50.79 million.

Sophiris Bio (NASDAQ:SPHS) last released its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.06. Analysts anticipate that Sophiris Bio Inc. will post ($0.73) earnings per share for the current fiscal year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.